Literature DB >> 32352077

Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.

Oldham Ce1, Powell Rs1, Williams Ab1, Dixon S1, Wooten Cj1, Melendez Qm1, Lopez D1.   

Abstract

Alzheimer's disease [AD] is not only the most common neurodegenerative disease but is also currently incurable. Proprotein convertase subtilisin/kexin-9 [PCSK9] is an indirect regulator of plasma low density lipoprotein [LDL] levels controlling LDL receptor expression at the plasma membrane. PCSK9 also appears to regulate the development of glucose intolerance, insulin resistance, abdominal obesity, inflammation, and hypertension, conditions that have been identified as risk factors for AD. PCSK9 levels also depend on age, sex, and ethnic background, factors associated with AD. Herein, we will review indirect evidence that suggests a link between PCSK9 levels and AD.

Entities:  

Keywords:  Alzheimer’s disease; LDL; Metabolic diseases; PCSK9

Year:  2018        PMID: 32352077      PMCID: PMC7189778          DOI: 10.31531/2581-4745.1000106

Source DB:  PubMed          Journal:  Int J Biomed Investig        ISSN: 2581-4745


  2 in total

Review 1.  Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9.

Authors:  Klaus-Dieter Schlüter; Annemarie Wolf; Rolf Schreckenberg
Journal:  Front Physiol       Date:  2020-12-07       Impact factor: 4.566

2.  No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.

Authors:  Laura E Korthauer; Robert P Giugliano; Jianping Guo; Marc S Sabatine; Peter Sever; Anthony Keech; Dan Atar; Christopher Kurtz; Christian T Ruff; Francois Mach; Brian R Ott
Journal:  PLoS One       Date:  2022-04-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.